Prophylactic HIV Drugs Market Insights, Research and Growth Factor till 2028
In 2021, the Global Prophylactic HIV Drugs Market is expected to be worth around $30 billion. Furthermore, with rising HIV infection rates worldwide and increased awareness about HIV AIDS prevention, the demand for prophylactic HIV drugs is expected to grow at a 4% CAGR between 2022 and 2032, reaching more than US$ 40 billion in 2028. Human immunodeficiency virus (HIV) has become one of the leading causes of death worldwide, affecting millions of people over the years. The virus attacks infected patients’ immune systems, making them vulnerable to a variety of infections and cancers. Although there is no permanent cure for HIV, the condition can be managed by increasing access to effective prevention, diagnosis, treatment, and care. One of the major factors driving demand for prophylactic HIV drugs is a growing emphasis on preventing HIV acquisition. Prophylactic HIV drugs are advanced therapeutics used to prevent HIV infection in specific situations. They are especially effectiv...